Acadia Pharmaceuticals | ACAD - Sales Revenues



Acadia Pharmaceuticals reported $264.6M in Sales Revenues for its fiscal quarter ending in June of 2025.


Sales Change Date
Acadia Pharmaceuticals USD 264.6M 20.28M Jun/2025
ALKERMES USD 390.7M 84.2M Jun/2025
Alnylam Pharmaceuticals USD 773.69M 179.5M Jun/2025
Biogen USD 2.6B 170M Jun/2025
BioMarin Pharmaceutical USD 825M 80M Jun/2025
Bristol-Myers Squibb USD 12.27B 1.07B Jun/2025
Corcept Therapeutics USD 194.4M 37.2M Jun/2025
Cytokinetics USD 66.76M 65.16M Jun/2025
Eisai JPY 202.65B 14.41B Jun/2025
Eli Lilly USD 15.56B 2.83B Jun/2025
Incyte USD 1.06B 10M Jun/2025
J&J USD 23.74B 1.85B Jun/2025
Moderna USD 142M 34M Jun/2025
Neurocrine Biosciences USD 687.5M 114.9M Jun/2025
Pfizer USD 14.7B 980M Jun/2025
Prothena USD 4.42M 2.3M Jun/2025
PTC Therapeutics USD 178.9M 11.1M Jun/2025
Sarepta Therapeutics USD 611.09M 163.81M Jun/2025
Ultragenyx Pharmaceutical USD 166.5M 27.21M Jun/2025
Vertex Pharmaceuticals USD 2.96B 190M Jun/2025